The Philadelphia Immunization Program is conducting its annual Provider Satisfaction Survey, and we want your input!
This survey will take about 5 minutes to complete. To thank you for your time, all survey respondents will receive laminated vaccine schedules. The first 10 respondents will also receive the 13th Edition Epidemiology and Prevention of Vaccine-Preventable Diseases (the “Pink Book”).
Please respond to this survey by March 23rd, 2017. Follow the link below to begin:
We thank you for your participation!
The Advisory Committee on Immunization Practices (ACIP) approved the Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger. More information concerning the changes can be found here.
The Advisory Committee on Immunization Practices (ACIP) also voted to approve the Recommended Adult Immunization Schedule for Adults Aged 19 Years or Older. More information concerning the changes can be found here.
To download or print the new 2017 Immunization Schedules navigate to the CDC Immunization Schedules Webpage.
FluLaval Only Pediatric Flu Vaccine Available Through VFC: Now Can Be Administered to Children 6 Months and Older
On November 18, 2016, the Food and Drug Administration approved an extension of the age range of quadrivalent FluLaval IIV to include children 6 through 35 months of age. FluLaval was previously approved for people 3 years of age and older. The vaccine will be supplied by VFC for this indication in multi-dose vials. The dosage approved for children 6 through 35 months of age is 0.5 mL – the same dosage as for people 3 years of age and older.
ACIP has not yet issued a recommendation regarding the use of FluLaval in children 6 through 35 months of age. However, clinicians are free to use this and other vaccines in a manner consistent with their FDA labeling. More information about FluLaval® and the updated recommendation can be found on the GSK Website.
The immunization program currently has two different VFAAR flu vaccines available for use.
VFAAR (adult) flu vaccines include:
|Afluria®||Seqirus||19+ years||Inactivated, trivalent||33332-0016-01||10 pack single dose syringe|
|*Fluvirin®||Seqirus||19+ years||Inactivated, trivalent||70461-0119-10||5mL multi-dose vial, 10 dose vial|
*Fluvirin® is available in very limited quantities.
Due to limited shipping availability by our distribution center, orders received after December 13th noon may not be shipped out until January 2017. You will still be able to submit orders for approval.
Please contact the VFC or VFAAR program if you need assistance.
Provider Education Coordinators – Jillian Brown and Mohan Nagaraja
DPHProviderhelp@phila.gov; 215-685-6872 or 215-685-6490
VFC Coordinator – Shumethia Seal
VFAAR Coordinator – Joani Schmeling